Pharma Focus Asia
KP - Sustainable Packaging Solutions

WuXi Biologics Plans to Expand its Manufacturing Facility in Massachusetts, USA


WuXi Biologics plans to increase its total manufacturing facility in Massachusetts USA.


The facility is deisgned to increase the total manufacturing capacity 36,000 litres. The construction of the 189,500-square-foot facility is currently in progress. 

The new facility will now have the capability to produce 12,000 more litres of commercial drug substance than originally planned, bringing the total planned capacity to 24,000 litres.

This expanded capacity aims to streamline manufacturing processes, making more efficient and cost-effective, ultimately facilitating the production of new biologics for patients.

The facility is expected to commence operations in 2025, and the good manufacturing practise (GMP) release is anticipated in 2026.

When the site reaches full operational capacity, it is anticipated to have a workforce of 250 individuals.


Name    WuXi Biologics
Type     Expansion
Year      2025


Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024Equinix accelerated medical research...CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?